Display options
Cite
Qian C, Liu X, Xu Q, et al. Recent Progress on the Versatility of Virus-Like Particles. Vaccines (Basel). 2020;8(1)doi: 10.3390/vaccines8010139.
Qian, C., Liu, X., Xu, Q., Wang, Z., Chen, J., Li, T., Zheng, Q., Yu, H., Gu, Y., Li, S., & Xia, N. (2020). Recent Progress on the Versatility of Virus-Like Particles. Vaccines, 8(1), . https://doi.org/10.3390/vaccines8010139
Qian, Ciying, et al. "Recent Progress on the Versatility of Virus-Like Particles." Vaccines vol. 8,1 (2020). doi: https://doi.org/10.3390/vaccines8010139
Qian C, Liu X, Xu Q, Wang Z, Chen J, Li T, Zheng Q, Yu H, Gu Y, Li S, Xia N. Recent Progress on the Versatility of Virus-Like Particles. Vaccines (Basel). 2020 Mar 20;8(1). doi: 10.3390/vaccines8010139. PMID: 32244935; PMCID: PMC7157238.
Copy Download .nbib Format: NLM
Share it on

Vaccines (Basel). 2020 Mar 20;8(1). doi: 10.3390/vaccines8010139.

Recent Progress on the Versatility of Virus-Like Particles.

Vaccines

Ciying Qian, Xinlin Liu, Qin Xu, Zhiping Wang, Jie Chen, Tingting Li, Qingbing Zheng, Hai Yu, Ying Gu, Shaowei Li, Ningshao Xia

Affiliations

  1. National Institute of Diagnostics and Vaccine Development in Infectious Disease, School of Life Sciences, Xiamen University, Xiamen 361102, China.
  2. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University, Xiamen 361102, China.

PMID: 32244935 PMCID: PMC7157238 DOI: 10.3390/vaccines8010139

Abstract

Virus-like particles (VLPs) are multimeric nanostructures composed of one or more structural proteins of a virus in the absence of genetic material. Having similar morphology to natural viruses but lacking any pathogenicity or infectivity, VLPs have gradually become a safe substitute for inactivated or attenuated vaccines. VLPs can achieve tissue-specific targeting and complete and effective cell penetration. With highly ordered epitope repeats, VLPs have excellent immunogenicity and can induce strong cellular and humoral immune responses. In addition, as a type of nanocarrier, VLPs can be used to display antigenic epitopes or deliver small molecules. VLPs have thus become powerful tools for vaccinology and biomedical research. This review highlights the versatility of VLPs in antigen presentation, drug delivery, and vaccine technology.

Keywords: nanocarrier; recombinant vaccine; virus-like particles

References

  1. J Virol. 2005 Nov;79(21):13656-66 - PubMed
  2. Appl Environ Microbiol. 2015 Feb;81(3):882-9 - PubMed
  3. Vaccines (Basel). 2020 Feb 22;8(1): - PubMed
  4. J Virol. 2007 Jul;81(13):7111-23 - PubMed
  5. J Infect Dis. 2015 Mar 15;211(6):870-8 - PubMed
  6. N Engl J Med. 1980 Oct 9;303(15):833-41 - PubMed
  7. Immunity. 2018 Oct 16;49(4):695-708.e4 - PubMed
  8. Vaccine. 2020 Apr 9;38(17):3378-3386 - PubMed
  9. J Immunol. 2004 Feb 1;172(3):1777-85 - PubMed
  10. Expert Opin Biol Ther. 2008 Feb;8(2):235-47 - PubMed
  11. Chem Biol. 2007 Oct;14(10):1152-62 - PubMed
  12. mBio. 2017 Sep 26;8(5): - PubMed
  13. NPJ Vaccines. 2018 Jan 23;3:3 - PubMed
  14. N Engl J Med. 2012 Dec 13;367(24):2284-95 - PubMed
  15. Front Plant Sci. 2019 Jun 20;10:779 - PubMed
  16. Hepatology. 2001 Oct;34(4 Pt 1):798-802 - PubMed
  17. Curr Opin Virol. 2016 Jun;18:44-9 - PubMed
  18. J Mark Access Health Policy. 2017 Aug 31;5(1):1336044 - PubMed
  19. Curr Gene Ther. 2013 Dec;13(6):421-33 - PubMed
  20. Drugs Today (Barc). 2018 Jul;54(7):399-405 - PubMed
  21. Virology. 1995 Jan 10;206(1):126-35 - PubMed
  22. N Engl J Med. 2007 May 10;356(19):1928-43 - PubMed
  23. Prog Lipid Res. 2000 Jan;39(1):3-18 - PubMed
  24. Nat Immunol. 2008 Jan;9(1):54-62 - PubMed
  25. Vaccine. 2013 Jan 7;31(3):524-32 - PubMed
  26. J Virol. 2000 Oct;74(19):8966-71 - PubMed
  27. Vaccine. 2014 Sep 3;32(39):5041-8 - PubMed
  28. J Am Chem Soc. 2009 Dec 2;131(47):17093-5 - PubMed
  29. N Engl J Med. 2011 Dec 8;365(23):2178-87 - PubMed
  30. JAMA. 1987 May 15;257(19):2612-6 - PubMed
  31. Vaccine. 2002 Mar 15;20(13-14):1803-8 - PubMed
  32. Travel Med Infect Dis. 2006 Dec;4(6):313-8 - PubMed
  33. Expert Rev Vaccines. 2008 Oct;7(8):1141-50 - PubMed
  34. Emerg Microbes Infect. 2018 Sep 26;7(1):160 - PubMed
  35. Hum Vaccin Immunother. 2015;11(7):1717-24 - PubMed
  36. Ann Med. 2018 Mar;50(2):110-120 - PubMed
  37. J Infect Dis. 2018 Jan 30;217(4):597-607 - PubMed
  38. Hemodial Int. 2005 Oct;9(4):367-75 - PubMed
  39. Vaccine. 2011 Oct 19;29(45):8126-33 - PubMed
  40. PLoS One. 2019 Mar 7;14(3):e0210477 - PubMed
  41. Vaccine. 2017 Aug 16;35(35 Pt B):4637-4645 - PubMed
  42. Vaccine. 2017 Sep 5;35(37):5073-5080 - PubMed
  43. Curr Opin Virol. 2013 Jun;3(3):357-62 - PubMed
  44. Emerg Microbes Infect. 2018 May 18;7(1):94 - PubMed
  45. Adv Biotechnol Processes. 1990;14:279-99 - PubMed
  46. Isr Med Assoc J. 2001 May;3(5):328-32 - PubMed
  47. Hum Vaccin Immunother. 2018 Jan 2;14(1):17-27 - PubMed
  48. Eur J Immunol. 2012 Nov;42(11):3049-61 - PubMed
  49. J Gen Intern Med. 1986 May-Jun;1(3):199-201 - PubMed
  50. PLoS One. 2009;4(5):e5569 - PubMed
  51. Bioconjug Chem. 2007 Jul-Aug;18(4):1140-7 - PubMed
  52. Mol Ther. 2009 May;17(5):767-77 - PubMed
  53. JAMA. 1983 Feb 11;249(6):745-6 - PubMed
  54. Risk Anal. 2006 Dec;26(6):1471-505 - PubMed
  55. Biotechnol Bioeng. 2007 Dec 1;98(5):968-77 - PubMed
  56. Lancet. 2007 Jun 30;369(9580):2161-2170 - PubMed
  57. Semin Immunol. 2017 Dec;34:123-132 - PubMed
  58. Hum Vaccin Immunother. 2012 Jun;8(6):823-7 - PubMed
  59. Sci Rep. 2019 Mar 27;9(1):5260 - PubMed
  60. N Engl J Med. 2018 Jun 14;378(24):2346-2348 - PubMed
  61. J Natl Cancer Inst. 2020 Feb 1;112(2):145-153 - PubMed
  62. Virol J. 2018 Apr 2;15(1):60 - PubMed
  63. Hum Vaccin Immunother. 2015;11(4):908-14 - PubMed
  64. JCI Insight. 2018 Jul 12;3(13): - PubMed
  65. Acta Biochim Pol. 2014;61(3):531-9 - PubMed
  66. Trends Biotechnol. 2013 Nov;31(11):654-63 - PubMed
  67. Nanomedicine. 2010 Oct;6(5):634-41 - PubMed
  68. Clin Immunol. 2017 Oct;183:99-108 - PubMed
  69. JAMA. 2018 Feb 27;319(8):822-823 - PubMed
  70. Hum Vaccin. 2010 Apr;6(4):346-54 - PubMed
  71. Expert Rev Vaccines. 2018 Sep;17(9):773-784 - PubMed
  72. Expert Rev Vaccines. 2009 Apr;8(4):435-45 - PubMed
  73. Vaccine. 1994 Nov;12(15):1453-9 - PubMed
  74. Clin Exp Immunol. 2017 Sep;189(3):331-341 - PubMed
  75. J Immunol. 2004 Oct 1;173(7):4308-16 - PubMed
  76. Hum Vaccin. 2010 May;6(5):407-19 - PubMed
  77. Nat Commun. 2018 Dec 18;9(1):5360 - PubMed
  78. J Infect Dis. 2016 Sep 15;214(6):845-53 - PubMed
  79. Vaccine. 2017 Oct 9;35(42):5714-5721 - PubMed
  80. Kidney Int. 2005 Nov;68(5):2298-303 - PubMed
  81. JAMA. 2016 Dec 13;316(22):2411-2421 - PubMed
  82. Immun Ageing. 2017 Apr 12;14:8 - PubMed
  83. Sci Rep. 2016 Apr 28;6:25141 - PubMed
  84. Intervirology. 2002;45(4-6):371-80 - PubMed
  85. J Exp Med. 1997 May 19;185(10):1785-92 - PubMed
  86. Gut. 2020 Feb;69(2):343-354 - PubMed
  87. Hepatol Int. 2017 Nov;11(6):500-508 - PubMed
  88. Curr Opin Struct Biol. 2000 Apr;10(2):170-3 - PubMed
  89. Lancet Infect Dis. 2017 Aug;17(8):843-853 - PubMed
  90. Sci Rep. 2017 Apr 19;7:46621 - PubMed
  91. N Engl J Med. 2007 Mar 1;356(9):895-903 - PubMed
  92. Vaccines (Basel). 2018 Jul 02;6(3): - PubMed
  93. Vaccine. 2008 Sep 2;26(37):4795-808 - PubMed
  94. Nihon Rinsho. 2009 Jan;67(1):62-8 - PubMed
  95. Vaccine. 2012 May 21;30(24):3580-6 - PubMed
  96. Vaccine. 2005 Apr 22;23(22):2893-901 - PubMed
  97. Eur J Epidemiol. 1988 Jun;4(2):256-8 - PubMed
  98. Curr Opin Infect Dis. 2019 Oct;32(5):435-444 - PubMed
  99. Vaccine. 2012 Mar 28;30(15):2556-63 - PubMed
  100. Vaccine. 2002 Aug 19;20(25-26):3155-64 - PubMed
  101. Vaccine. 2006 Jun 19;24(25):5320-6 - PubMed
  102. J Immunol. 2014 Jun 15;192(12):5499-508 - PubMed
  103. Lancet. 2010 Sep 11;376(9744):895-902 - PubMed
  104. Hum Vaccin Immunother. 2020;16(1):33-41 - PubMed
  105. Vaccine. 2020 Jan 22;38(4):830-839 - PubMed
  106. Vaccine. 2018 Feb 1;36(6):873-880 - PubMed
  107. Nanomedicine. 2015 Jan;11(1):67-76 - PubMed
  108. N Engl J Med. 2007 May 10;356(19):1915-27 - PubMed
  109. Sci Rep. 2016 Nov 24;6:37891 - PubMed

Publication Types

Grant support